DeSoto Peptides Research Journal | October 2026
The growing interest in Retatrutide and MOTS-C reflects an important development in metabolic research: scientists are investigating not only how the body regulates appetite and weight, but also how individual cells respond to changing energy demands.
Retatrutide has attracted attention for its triple hormone receptor activity and substantial weight-loss findings in clinical trials. MOTS-C, meanwhile, is being investigated for its role in mitochondrial signaling, glucose metabolism, and cellular adaptation to metabolic stress.
Although these compounds act through different biological mechanisms, their respective research has raised an interesting question:
Could studying appetite regulation and cellular energy signaling together provide a more complete understanding of metabolic health?
This article examines the science behind both peptides, their individual mechanisms, published research findings, and why they are frequently discussed together in the field of metabolic research.
What Is Retatrutide?
Retatrutide, also identified as LY3437943, is an investigational peptide developed by Eli Lilly.
Unlike medications that target only one or two metabolic hormone receptors, Retatrutide activates three:
GLP-1 (glucagon-like peptide-1): Involved in appetite, satiety, gastric emptying, and glucose regulation.
GIP (glucose-dependent insulinotropic polypeptide): Participates in insulin signaling and metabolic regulation.
Glucagon: Influences hepatic glucose metabolism, fuel availability, and energy expenditure.
This triple receptor activity distinguishes Retatrutide from semaglutide, which primarily activates GLP-1 receptors, and tirzepatide, which activates GLP-1 and GIP receptors.
Researchers are particularly interested in the additional glucagon receptor activity because it may influence energy expenditure and nutrient utilization alongside appetite regulation.
Retatrutide and Metabolic Regulation
Retatrutide's mechanism is especially interesting because body-weight regulation involves more than appetite alone.
The body continuously coordinates food intake, insulin secretion, nutrient storage, glucose production, and energy expenditure.
Through its GLP-1, GIP, and glucagon receptor activity, Retatrutide allows researchers to investigate several of these processes simultaneously.
GLP-1 signaling contributes to reduced appetite and increased satiety. GIP participates in glucose-dependent insulin secretion and additional metabolic processes. Glucagon receptor activation influences hepatic energy metabolism and may contribute to changes in energy expenditure.
The combined activity of these pathways has made Retatrutide an important subject of modern obesity and metabolic research.
Retatrutide Clinical Trial Findings
Retatrutide has demonstrated substantial body-weight reductions in clinical trials.
In a 2023 Phase 2 clinical trial published in The New England Journal of Medicine, participants receiving the highest studied Retatrutide dose experienced an average weight reduction of 24.2% after 48 weeks.
The findings generated considerable interest because they demonstrated the potential of simultaneously targeting three metabolic hormone receptors.
Retatrutide Phase 3 Research
In May 2026, Eli Lilly announced results from its Phase 3 TRIUMPH-1 study.
The reported average weight reductions at 80 weeks were:
Retatrutide Trial GroupAverage Weight Reduction4 mg19.0%9 mg25.9%12 mg28.3%
The study also reported improvements in several cardiovascular and metabolic risk markers, including:
Waist circumference
Triglyceride levels
Non-HDL cholesterol
Systolic blood pressure
Additional measures of metabolic health
These findings demonstrate the potential significance of triple receptor agonism in metabolic research.
However, the results represent specific clinical trial populations and treatment conditions. They do not establish that every individual would experience comparable results.
Importantly, these trials investigated Retatrutide itself rather than its combination with MOTS-C.
What Is MOTS-C?
MOTS-C stands for mitochondrial open reading frame of the 12S rRNA type-c.
It is a naturally occurring, 16-amino-acid peptide encoded by mitochondrial DNA.
Mitochondria are commonly described as the energy-producing structures within cells. They are responsible for generating much of the adenosine triphosphate (ATP) used to support cellular activity.
However, mitochondrial function extends beyond ATP production.
Mitochondria also participate in metabolic communication, stress responses, and signaling pathways that help cells adjust to changing energy conditions.
MOTS-C belongs to an emerging class of molecules known as mitochondrial-derived peptides.
These peptides have attracted scientific attention because they may help coordinate communication between mitochondrial activity and broader cellular metabolic processes.
Why MOTS-C Is Important to Metabolic Research
MOTS-C research has focused on several interconnected biological processes:
Cellular glucose utilization
Insulin sensitivity
Metabolic stress responses
AMPK-associated signaling
Skeletal muscle metabolism
Mitochondrial communication
Age-associated changes in metabolic function
Unlike Retatrutide, which directly activates specific hormone receptors, MOTS-C is primarily investigated for its relationship with intracellular signaling and cellular responses to energy availability.
This difference is one reason the two compounds are frequently compared in discussions of metabolic regulation.
MOTS-C and AMPK Signaling
One of the most significant aspects of MOTS-C research involves AMPK, or AMP-activated protein kinase.
AMPK functions as a cellular energy sensor.
When cellular energy availability changes, AMPK participates in signaling processes that help coordinate energy production and consumption.
These processes are relevant to:
Glucose uptake and utilization
Cellular responses to energy stress
Fatty acid metabolism
Skeletal muscle energy regulation
Maintenance of metabolic balance
AMPK does not function as a simple switch that automatically causes fat loss.
Instead, it forms part of a larger network of pathways responsible for helping cells adapt to changing energy requirements.
The Original MOTS-C Research
A landmark 2015 study published in Cell Metabolism identified important relationships between MOTS-C and metabolic regulation.
Researchers observed that MOTS-C influenced metabolic pathways associated with insulin sensitivity and glucose utilization.
In mouse experiments, MOTS-C administration also demonstrated protection against diet-related obesity and insulin resistance.
These findings established MOTS-C as an important candidate for further investigation into cellular metabolism.
However, results observed in cells and animal models do not establish equivalent effects from administered MOTS-C in humans.
MOTS-C and Mitochondrial Communication
Additional research has explored how MOTS-C participates in communication between mitochondria and the cell nucleus.
A 2018 study published in Cell Metabolism demonstrated that MOTS-C can move into the cell nucleus under certain metabolic stress conditions.
Once in the nucleus, MOTS-C was associated with changes in gene expression related to cellular stress responses.
The researchers described an AMPK-dependent process connecting mitochondrial signaling with nuclear activity.
This is particularly interesting because it suggests that mitochondrial-derived peptides may participate in broader cellular regulatory systems rather than functioning only within mitochondria.
Understanding these signaling relationships may help researchers investigate how cells respond to metabolic stress, changes in nutrient availability, and altered energy demands.
MOTS-C, Exercise, and Skeletal Muscle Research
Another important area of MOTS-C investigation involves physical activity.
A 2021 study published in Nature Communications examined MOTS-C in relation to exercise, muscle function, and aging.
Researchers reported that exercise increased naturally occurring MOTS-C levels in human skeletal muscle and circulation.
The study also included experiments in mice demonstrating improvements in certain measures of physical performance following MOTS-C administration.
These findings supported further interest in mitochondrial-derived peptides and their relationship with skeletal muscle metabolism.
However, there is an important distinction between observing naturally occurring MOTS-C responses during human exercise and demonstrating benefits from administering the peptide.
The human findings documented changes in endogenous MOTS-C associated with exercise. The experimental intervention findings concerning physical performance came from animal studies.
Further human research is necessary to determine whether administered MOTS-C produces similar effects.
Why Are Retatrutide and MOTS-C Discussed Together?
Retatrutide and MOTS-C have different primary research mechanisms, but both are attracting significant interest in metabolic science.
Retatrutide influences hormone receptors involved in appetite regulation, glucose metabolism, and energy balance.
MOTS-C is associated with mitochondrial signaling, cellular energy sensing, and metabolic responses to physiological stress.
One important distinction in metabolic research is that regulating food intake and regulating cellular energy utilization are related but separate biological processes.
Understanding these different pathways helps explain why Retatrutide and MOTS-C are frequently discussed together.
Retatrutide: Hormonal Regulation
Retatrutide activates GLP-1, GIP, and glucagon receptors, allowing researchers to investigate how multiple hormonal pathways influence appetite, body weight, and metabolic function.
Clinical trials have demonstrated substantial reductions in body weight alongside improvements in several metabolic health markers.
MOTS-C: Cellular Energy Signaling
MOTS-C research focuses on how cells detect and respond to changes in energy availability.
Its relationship with AMPK activity, mitochondrial communication, and metabolic adaptation has attracted attention in experimental studies examining insulin sensitivity, skeletal muscle activity, and cellular stress responses.
The Scientific Connection
Retatrutide research examines how hormonal signaling influences whole-body energy regulation.
MOTS-C research investigates how cellular pathways participate in metabolic adaptation and energy utilization.
Together, these two areas of research provide different perspectives on the complex biological systems responsible for metabolic regulation.
Although their mechanisms are potentially complementary, controlled human studies have not established that combining Retatrutide and MOTS-C improves weight loss, preserves muscle mass, or prevents metabolic adaptation.
Retatrutide, MOTS-C, and Energy Expenditure
Energy expenditure is an important area of metabolic investigation.
The human body uses energy to maintain essential biological functions, support physical activity, regulate body temperature, and perform numerous cellular processes.
During periods of weight loss, energy expenditure may change as body mass, nutritional intake, and metabolic signaling adapt.
Retatrutide and MOTS-C are scientifically interesting in this context because they relate to different aspects of energy regulation.
Retatrutide's glucagon receptor activity has generated interest in potential effects on energy expenditure alongside its appetite-related activity.
MOTS-C has been investigated for its relationship with energy-sensing pathways and metabolic adaptation.
These are distinct mechanisms, and their biological relationship remains an area for further study.
Could MOTS-C Prevent Metabolic Slowdown?
One frequently discussed question is whether mitochondrial-derived peptides could influence metabolic adaptation during periods of reduced energy intake.
Because MOTS-C participates in cellular metabolic signaling, researchers are interested in understanding whether it may affect processes involved in energy utilization and metabolic stress.
However, current evidence does not establish that administering MOTS-C prevents metabolic slowdown during Retatrutide-associated weight loss.
Nor has the combination been demonstrated in controlled human studies to preserve muscle mass, increase fat loss beyond Retatrutide alone, or prevent changes in resting energy expenditure.
These remain research questions rather than clinically established outcomes.
Retatrutide, MOTS-C, and Insulin Sensitivity
Insulin sensitivity is another area connecting the broader research surrounding both peptides.
Insulin helps regulate glucose uptake and storage throughout the body.
When cells respond less effectively to insulin, glucose regulation can become impaired.
Retatrutide influences several hormone pathways involved in glucose regulation, including GLP-1 and GIP signaling.
MOTS-C has demonstrated relationships with insulin sensitivity and metabolic pathways in preclinical experiments.
The 2015 MOTS-C study reported improvements in metabolic regulation in experimental models, including protection against diet-related insulin resistance in mice.
These findings make insulin signaling an interesting subject when comparing the biological research surrounding Retatrutide and MOTS-C.
Nevertheless, improvements observed with each compound individually do not establish additional benefits from combining them.
How the Research Evidence Compares
Although Retatrutide and MOTS-C are often discussed together, the strength of the available evidence differs substantially.
Research AreaRetatrutideMOTS-CPrimary research focusTriple hormone receptor activityMitochondrial and cellular signalingMajor pathwaysGLP-1, GIP, glucagonAMPK and metabolic stress pathwaysHuman researchPhase 2 and Phase 3 clinical trialsHuman observations of naturally occurring MOTS-CBody-weight findingsSubstantial reductions in clinical trialsMetabolic findings primarily from preclinical studiesEnergy expenditureInvestigated through hormonal metabolic mechanismsInvestigated through cellular energy signalingInsulin sensitivityHuman metabolic clinical dataExperimental and preclinical findingsCombined administrationNo established clinical benefit with MOTS-CNo established clinical benefit with Retatrutide
This difference matters when interpreting claims about the two compounds.
Retatrutide has substantial interventional human clinical data.
MOTS-C has compelling experimental findings involving mitochondrial and metabolic biology, but considerably less human evidence involving administration of the peptide.
Research into both compounds can contribute to understanding metabolic regulation without assuming that their combination provides additional benefits.
The Future of Metabolic Peptide Research
Metabolic research is moving beyond the idea that energy regulation is controlled by one hormone or one biological pathway.
Scientists are investigating complex interactions involving:
Appetite and satiety regulation
Glucose and insulin signaling
Skeletal muscle metabolism
Hormonal regulation of energy balance
Mitochondrial communication
Cellular energy sensing
Metabolic adaptation
Responses to physiological stress
Retatrutide and MOTS-C represent two different areas of this investigation.
Retatrutide demonstrates how targeting multiple hormone receptors can substantially influence body weight and metabolic markers.
MOTS-C illustrates how mitochondrial-derived signaling molecules may participate in broader metabolic adaptation and cellular regulation.
Future research may clarify how these different systems interact and whether investigating them together provides meaningful scientific insights.
Final Thoughts: Understanding Retatrutide and MOTS-C Research
The scientific interest surrounding Retatrutide and MOTS-C comes from their different relationships with metabolic regulation.
Retatrutide is being studied for its activity across three hormone receptors and its effects on body weight and metabolic health.
MOTS-C is being investigated for its relationship with AMPK signaling, mitochondrial communication, and cellular responses to metabolic stress.
While these pathways are biologically related, the clinical benefits of combining the two compounds have not been established.
For researchers following developments in metabolic peptides, both represent important areas of continued scientific investigation.
As research progresses, a better understanding of hormonal signaling, mitochondrial communication, and cellular energy regulation may contribute to the development of new approaches to metabolic science.
Published Research and Scientific References
1. Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
2. Eli Lilly and Company (2026). Retatrutide TRIUMPH-1 Phase 3 Clinical Trial Results.
3. Lee C, et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism.
4. Kim KH, et al. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism.
5. Reynolds JC, et al. (2021). MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis. Nature Communications.
Research Disclaimer: This article is provided by DeSoto Peptides for educational and scientific information only. Retatrutide and MOTS-C are investigational compounds and are not FDA-approved for general human use. This article does not recommend administering, combining, or purchasing these compounds for personal use and does not constitute medical advice.